Wu, Xue-Feng <br/><br/>
Beauvericin ameliorates experimental colitis by inhibiting activated T cells via downregulation of the PI3K/Akt signaling pathway.  [electronic resource] 

 -  PloS one  2013 
 - e83013 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1932-6203 
<br/><br/><label>Standard No.: </label>10.1371/journal.pone.0083013  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Apoptosis<br/>Cell Proliferation--drug effects<br/>Colitis--chemically induced<br/>Depsipeptides--therapeutic use<br/>Disease Models, Animal<br/>Down-Regulation<br/>Female<br/>Flow Cytometry<br/>Gene Expression Regulation, Enzymologic<br/>Inflammation<br/>Interferon-gamma--metabolism<br/>Lymphocyte Activation--drug effects<br/>Membrane Potential, Mitochondrial--drug effects<br/>Mice<br/>Mice, Inbred BALB C<br/>Phosphatidylinositol 3-Kinases--metabolism<br/>Phosphorylation<br/>Proto-Oncogene Proteins c-akt--metabolism<br/>Signal Transduction<br/>T-Lymphocytes--drug effects<br/>Trinitrobenzenesulfonic Acid--chemistry<br/>Tumor Necrosis Factor-alpha--metabolism